iBio Inc [AMEX: IBIO] surged by $0.7 during the normal trading session on while it closed the day at $4.06. The company report on March 27, 2024 at 7:00 AM that iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –.
– iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets –.
iBio Inc stock has also gained 275.93% of its value over the past 7 days. However, IBIO stock has inclined by 185.92% in the 3 months of the year. Over the past six months meanwhile, it has lost -30.95% and gained 196.35% year-on date.
The market cap for IBIO stock reached $14.13 million, with 3.48 million shares outstanding and 3.47 million shares in the current float. Compared to the average trading volume of 2.85M shares, IBIO reached a trading volume of 50466054 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about iBio Inc [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for iBio Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on November 29, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on January 22, 2021, representing the official price target for iBio Inc stock. Previously, the target price had yet another raise to $2.55, while Alliance Global Partners analysts kept a Buy rating on IBIO stock.
The Average True Range (ATR) for iBio Inc is set at 0.35, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 282.58. The Price to Book ratio for the last quarter was 1.43, with the Price to Cash per share for the same quarter was set at 1.11.
IBIO stock trade performance evaluation
iBio Inc [IBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 275.93. With this latest performance, IBIO shares gained by 235.54% in over the last four-week period, additionally sinking by -30.95% over the last 6 months – not to mention a drop of -91.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 95.45, with the RSI for the last a single of trading hit 97.75, and the three-weeks RSI is set at 90.94 for iBio Inc [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.26, while it was recorded at 2.15 for the last single week of trading, and 5.34 for the last 200 days.
iBio Inc [IBIO]: An insightful look at the core fundamentals
iBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.91 and a Current Ratio set at 0.91.
Earnings per share (EPS) analysis for iBio Inc [IBIO] stock
With the latest financial reports released by the company, iBio Inc posted -2.05/share EPS, while the average EPS was predicted by analysts to be reported at -1.85/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -10.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBIO.
iBio Inc [IBIO]: Institutional Ownership
The top three institutional holders of IBIO stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in IBIO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in IBIO stock with ownership which is approximately 5.8325%.
